[August 14, 2017]

Myomo, Inc. Reports Second Quarter 2017 Results

Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a commercial stage medical robotics company, today reports its financial results for the three and six months ended June 30, 2017.

Highlights and Achievements in the Second Quarter 2017 and Year To-date:

The Company completed its initial public offering under SEC Regulation A+ on June 9, 2017 for total gross proceeds of approximately $8 million, including $5 million through the sale of shares and nearly $3 million in a concurrent private placement of units which include one share of common stock and one warrant. With growth capital raised during the quarter, 2Q and YTD 2017 results reflect business operations under a controlled product launch. Total revenue for the second quarter of 2017 grew 21% year over year to $307,000, compared to $254,000 for the second quarter of 2016. In addition to raising capital, Myomo accelerated its commercial activities:

• Obtained CE Mark approval for commercial sale of next-generation MyoPro® myoelectric arm orthosis across the European Economic Area. European launch preparations are underway, beginning in Germany with partner, Ottobock, the global market leader in technical orthopedics and prosthetics (O&P).
• Expanded sales and marketing team and increased marketing activity to expand MyoPro accessibility to more individuals in the U.S. and internationally.
• Established MyoPro Centers of Excellence at seven O&P practice organizations to create a network of 31 U.S. locations offering the MyoPro line of powered orthosis.
• Booked first set of orders under the distribution agreement with Ottobock for VA Medical Centers in the US;
• Announced publication of peer-reviewed clinical research conducted by the Ohio State University School of Medicine. The study concluded that upper extremity impairment is significantly reduced with use of the MyoPro, and these results exceeded the clinically important difference threshold of standard impairment tests.
• Launched next generation myoelectric arm orthosis, MyoPro 2 that extends the capabilities of the previous version with significant enhancements, including interchangeable, extended-life rechargeable batteries for continuous daily use; upgraded user interface; improved sensors; and enhanced harness and finger grasp orthosis for more reliable and comfortable long-term wear.

Paul R. Gudonis, Chairman & CEO of Myomo, commented: "We are very pleased to have successfully completed our IPO on June 9^th, the first JOBS Act / Regulation A+ offering to trade on a national exchange, NYSE American, formerly NYSE MKT. With the IPO funding, we expanded our sales and marketing initiatives to bring our proprietary technology to a large, underserved market. MyoPro is the only commercially available upper limb product line to restore or to improve functionality for patients with stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, MS, and ALS. In the U.S., MyoPro is currently available to veterans at Veterans Administration hospitals across the country and in over 30 O&P practice locations. After recently achieving the CE Mark, we now look forward to launching outside the U.S. The initial introduction of MyoPro is planned for Germany through our distributor partner, Ottobock, a well-established German-based technical O&P global leader."

Financial Results for the Second Quarter Ended June 30, 2017

Total revenue was $307,000 for the quarter ended June 30, 2017; an increase of $53,000, or 21%, as compared to the three months ended June 30, 2016. The increase was primarily due to $64,000 of grant revenue for new product development recognized during the three months ended June 30, 2017, which was partially offset by a $12,000 decrease in product revenue due to a higher proportion of distributor sales which have lower average selling prices.

Gross margin was 68% for the quarter ended June 30, 2017, as compared to 80% for the three months ended June 30, 2016. The decrease was due to distributor sales having lower average selling price than direct sales to customers and inventory and warranty provisions recorded as a result of our introduction of the next version of our MyoPro products.

Research and development expenses were $709,000, an increase of $450,000, or 174%, during the three months ended June 30, 2017, as compared to the three months ended June 31, 2016, primarily due to an incentive bonus of $300,000 to an engineering executive, increased expenses relating to the development of the next version of our MyoPro products, and higher engineering, testing, tooling, set-up and prototype costs.

Selling, general and administrative costs of $1,433,000 increased $799,000, or 126%, during the three months ended June 30, 2017, as compared to the three months ended June 30, 2016, primarily due to employee compensation, which primarily includes stock-based compensation expense, professional fees, travel expenses and an increase in clinical research to support reimbursement efforts for our products.

Interest and other expense, net of $5,448,000 increased $5,377,000 during the three months ended June 30, 2017, as compared to the three months ended June 30, 2016. The increase was primarily due to the non-recurring non-cash write off of $5,172,000 of unamortized debt discount associated with the conversion of the 2015 and 2016 convertible promissory notes into common stock and warrants.

The Company's net loss for the quarter ended June 30, 2017 amounted to $7,382,000, compared with a net loss of $760,000 for the corresponding 2016 period. Net loss available to common stockholders for the quarter ended June 30, 2017 was $7,755,000 or ($3.35) per share, compared with a net loss of $950,745, or ($0.94) per share, for the corresponding year ago period. The increase was primarily due to the non-recurring non-cash write off of $5,172,000 of unamortized debt discount associated with the conversion of the 2015 and 2016 convertible promissory notes into common stock and warrants.

Adjusted EBITDA¹ for the quarter ended June 30, 2017 was a loss of $1,656,000, compared with a loss of $670,000 for the corresponding 2016 period. A reconciliation of GAAP to this non-GAAP financial measure has been provided in the financial statement tables included in this press release. An explanation of this measure is also included below under the heading "Non-GAAP Financial Measures."

Cash on hand at June 30, 2017 was $7,110,000, compared to $797,000 at December 31, 2016. For the six months ended June 30, 2017, the Company used $2,747,000 of cash in operations, compared to $984,000 for the six months ended June 30, 2016. The increase in cash reflects the net proceeds from our IPO, and concurrent private placement, in addition to $1,770,000 of additional convertible notes issued since year-end, partially offset by the $2.7 million of net cash used in operating activities.

Conference Call and Webcast Information
Myomo will hold a conference call today, August 14, 2017 at 4:30 p.m. EDT. To access the conference call, please dial 1-866-807-9684 from the U.S. or 1-412-317-5415 internationally. Please instruct to be joined into Myomo's earnings conference call.

A replay of the conference call will be available approximately one hour after completion of the live conference call at the Investor Relations page. A dial-in replay of the call will be available until August 28, 2017; please dial 1-877-344-7529 from the U.S. or 1-412-317-0088 internationally and provide the passcode of 10111308.

(Tables follow)

About Myomo
Myomo, Inc. is a commercial stage medical robotics Company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Based on patented technology developed at MIT and the Company, Myomo develops and markets the MyoPro® product line of lightweight, non-invasive, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals that have suffered a stroke, spinal cord or nerve injury such as brachial plexus injury, or other neuromuscular disability such as amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). It is provided through clinical relationships with VA medical centers, leading rehabilitation hospitals, and Orthotics and Prosthetics ("O&P") practices. Several hundred have been successfully used by patients. It is the only device that, sensing a patient's own neurological signals through non-invasive sensors on the arm, can restore their ability to use their arms and hands so that they can return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. For more information, please visit www.myomo.com.

Forward Looking Statements
This press release contains forward-looking statements regarding the Company's future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. These factors include, among other things:

• our sales and commercialization efforts;
• our ability to achieve reimbursement from third-party payers for our products;
• our dependence upon external sources for the financing of our operations,
• our ability to effectively execute our business plan; and
• our expectations as to our clinical research program and clinical results.

More information about factors that potentially could affect our financial results is included in Myomo's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Non-GAAP Financial Measures
Myomo has provided in this release of financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. This information includes Adjusted EBITDA. This non-GAAP financial measure is not in accordance with, or an alternative for, GAAP and may be different from similar non-GAAP financial measures used by other companies. Myomo believes that the use of this non-GAAP financial measures provides supplementary information for investors to use in evaluating operating performance and in comparing its financial measures with other companies in Myomo's industry, many of which present similar non-GAAP financial measures. Adjusted EBITDA is EBITDA adjusted for the impact of the write off of unamortized debt discount associated with conversion of convertible notes into common stock and warrants, stock based-compensation and the impact of the fair value revaluation of our derivative liabilities. Non-GAAP financial measures that Myomo uses may differ from measures that other companies may use. This non-GAAP financial measure disclosed by Myomo is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP, and should be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of this non-GAAP measure to its most directly comparable GAAP financial measure. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables included as part of this press release.

¹ Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization adjusted the impact of the write off of unamortized debt discount associated with conversion of convertible notes into common stock and warrants, stock based-compensation and the impact of the fair value revaluation of our derivative liabilities.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170814005843/en/

[ Back To TMCnet.com's Homepage ]